Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Health Catalyst, Inc. Director's Dealing 2021

Dec 29, 2021

33681_dirs_2021-12-29_827bb220-ea64-4f86-8a18-06fc6453f91a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: Health Catalyst, Inc. (HCAT)
CIK: 0001636422
Period of Report: 2021-12-06

Reporting Person: Horstmeier Paul (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-06 Common Stock M 6063.00 $15.84 Acquired 105243.00 Direct
2021-12-06 Common Stock S 600.00 $37.9667 Disposed 104643.00 Direct
2021-12-06 Common Stock S 2674.00 $38.76 Disposed 101969.00 Direct
2021-12-06 Common Stock S 2789.00 $39.8888 Disposed 99180.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-12-06 Stock Option (Right to Buy) $15.84 M 6063.00 Disposed 2029-02-05 Common Stock (6063.00) Direct

Footnotes

F1: Due to a technical and administrative error, the original Form 4, filed on December 7, 2021, incorrectly reflected a sale of shares of Common Stock by the Reporting Person attributed to a vesting of Restricted Stock Units. We were recently made aware that the Reporting Person exercised options and sold shares from that option exercise. The exercise of those options and sale of shares is correctly reflected herein and the correct ownership tabulations are also included herein.

F2: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.

F3: Represents the weighted average sale price of the shares sold ranging from $37.47 to $38.43 per share, inclusive.

F4: Represents the weighted average sale price of the shares sold ranging from $38.47 to $39.24 per share, inclusive.

F5: Represents the weighted average sale price of the shares sold ranging from $39.66 to $40.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) through (5).

F6: 25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.